The pharmacogenetics and pharmacogenomics knowledge base: accentuating the knowledge by Hernandez-Boussard, Tina et al.
Published online 21 November 2007 Nucleic Acids Research, 2008, Vol. 36, Database issue D913–D918
doi:10.1093/nar/gkm1009
The pharmacogenetics and pharmacogenomics
knowledge base: accentuating the knowledge
Tina Hernandez-Boussard, Michelle Whirl-Carrillo, Joan M. Hebert, Li Gong,
Ryan Owen, Mei Gong, Winston Gor, Feng Liu, Chuong Truong, Ryan Whaley,
Mark Woon, Tina Zhou, Russ B. Altman and Teri E. Klein*
Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA
Received September 10, 2007; Revised and Accepted October 24, 2007
ABSTRACT
PharmGKB is a knowledge base that captures the
relationships between drugs, diseases/phenotypes
and genes involved in pharmacokinetics (PK) and
pharmacodynamics (PD). This information includes
literature annotations, primary data sets, PK and PD
pathways, and expert-generated summaries of
PK/PD relationships between drugs, diseases/
phenotypes and genes. PharmGKB’s website is
designed to effectively disseminate knowledge to
meet the needs of our users. PharmGKB currently
has literature annotations documenting the relation-
ship of over 500 drugs, 450 diseases and 600 variant
genes. In order to meet the needs of whole genome
studies, PharmGKB has added new functionalities,
including browsing the variant display by chromo-
some and cytogenetic locations, allowing the
user to view variants not located within a gene.
We have developed new infrastructure for
handling whole genome data, including increased
methods for quality control and tools for compar-
ison across other data sources, such as dbSNP,
JSNP and HapMap data. PharmGKB has also added
functionality to accept, store, display and query high
throughput SNP array data. These changes allow us
to capture more structured information on pheno-
types for better cataloging and comparison of data.
PharmGKB is available at www.pharmgkb.org
INTRODUCTION
The Pharmacogenetics and Pharmacogenomics Knowl-
edge Base (PharmGKB; www.pharmgkb.org) is a public
resource that promotes research into the relationships
between human genotypes, phenotypes and clinical
outcomes by linking and annotating primary data sets
from ongoing research and established data from the
literature (1,2). In addition to gene–drug relationships, the
PharmGKB also contains data on gene variation,
genomics, gene–disease relationships, drug action and
pathways. The PharmGKB has developed highly curated
pathways documenting the genes involved in pharmaco-
dynamics and pharmacokinetics of a selection of drugs.
We have developed an XML format for deﬁning
genotype data, a relational database schema for data
storage and a ﬂexible mechanism for submitting pheno-
type data (3). We are also participating in the PML eﬀort
to deﬁne an XML standard for genotype/phenotype data
exchange. PharmGKB ﬁrst came online in April 2000, and
major updates to the user interface appeared in 2002, 2004
and 2006. PharmGKB data and knowledge are updated
on a continuous basis. Access is free but requires users to
register for a username and password for viewing
individual subject data.
DISTINGUISHING PHARMGKB USER GROUPS
PharmGKB supplies a wide variety of pharmacogenomic
knowledge to a broad range of users, from gene-based
users to clinical scientists. In order to better serve our user
groups, PharmGKB has redesigned its website homepage
as well as the resource and submission tabs to more
eﬀectively disseminate knowledge in a form that matches
user needs. PharmGKB has identiﬁed four main user
groups of the database: gene-oriented users, drug-oriented
users, bioinformaticians and clinical/disease-oriented
investigators. PharmGKB organizes knowledge pertinent
to each group into user-based views and resources.
Figure 1 depicts the PharmGKB homepage that provides
direct links to diﬀerent user-based knowledge, such as
drug pages or gene pages and more speciﬁcally pharma-
cokinetic and pharmacodynamic data.
INTEGRATING GENOME-SCALE DATA
High-throughput functional genomic technologies have
resulted in the rapid accumulation of genome-scale
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variation, partly due to the haplotype mapping project
undertaken by HapMap(4). The interest lies in the notion
that a single nucleotide polymorphism (SNP) can con-
tribute directly to disease predisposition by modifying a
gene’s function, or that SNPs can be used as genetic
markers to tag near neighbor disease causing mutations
through association studies and linkage analysis. Genetic
variation is now measured on a genomic scale using SNP
arrays. The successful analysis of such data sets depends
on rapid access to the most current annotation of the
SNPs being studied in conjunction with phenotypic data,
linkage disequilibrium information and other genomic
data (5). Accordingly, PharmGKB has added function-
ality to integrate, aggregate and annotate data from
genome-wide studies. These data can be queried and
viewed by chromosome browsing, gene pages or
individual submission pages. Figure 2 shows the ABCB1
gene page that has been populated with an additional 15
variants from an Illumina 317K SNP array, assayed both
from traditional and high-throughput methods.
VIP GENE AND VARIANT PAGES
Very Important Pharmacogenes, provide annotated infor-
mation about genes, variants, haplotypes and splice
variants of particular relevance for pharmacogenetics
and pharmacogenomics. VIP gene pages highlight the
key variants, haplotypes, drugs, diseases and phenotypes
associated with the pharmacogene (Figure 3). A VIP gene
is deﬁned as a gene that has well-documented information
about its involvement in the pharmacodynamics or
pharmacokinetics of a drug. There are a total of about
200 well-documented VIP genes that were selected by
Figure 1. PharmGKB disseminates highly curated pharmacogenomic knowledge in a form that matches user needs.
D914 Nucleic Acids Research, 2008, Vol. 36, DatabaseissueFigure 2. PharmGKB VariantPage. CYP2D6 variant page contains information on the variants within the gene boundaries. SNP array data are
integrated with traditional PharmGKB primary data and other external variant data, such as dbSNP and JSNP.
Figure 3. PharmGKB very important pharmacogenomic (VIP) genes: PharmGKB gathers knowledge on key pharmacogenomic genes, which
highlight important variants, haplotypes, drugs, diseases and phenotypes associated with the gene.
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VIP pages are hand-curated and contain information
about the mapping of the variant to allow cross
comparison with other resources, frequencies and drug
and disease associations from key studies and the links to
the literature that document them. VIP variants link from
the variant page via a ﬂag in the row for that golden path
position.
PHARMGKB PATHWAYS
Historically, many pharmacogenetic studies have focused
on single genes involved in drug side-eﬀects. There is now
a growing interest in how pathways of interacting genes
can aﬀect both drug metabolism and drug response.
PharmGKB pathways are drug-centered, depicting candi-
date genes for pharmacogenetics and pharmacogenomics
studies and they provide the means to connect separate
data sets to represent the current knowledge as a cohesive
snapshot. Pathways are created based on community
interest and involvement/contributions. The diagrams
have information content in the shape and color of the
icons that represent whether the component is a gene,
drug, metabolic intermediate, etc. (Figure 4). The path-
ways are interactive: clicking on a gene takes the user to
the gene page from which available genotype and
































Figure 4. PharmGKB Irinotecan Pathway. View of a model human liver cell showing blood, bile, and intestinal compartments, indicating tissue-
speciﬁc involvement of genes in the irinotecan pathway. Drugs are depicted by purple boxes, transporter genes by turquoise ovals and genes coding
for metabolic enzymes by blue ovals. Available at: http://www.pharmgkb.org/search/pathway/irinotecan/liver.jsp.
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Clicking on a drug takes the user to the drug page from
which available phenotype data and literature citations
can be found. Clicking on a golden arrow presents the user
with phenotype data that support a relationship. In
addition to the pathway diagram, a summary is provided
to describe the content of the graphic. The pathways are
generated by collaboration of investigators and represent
a consensus of the opinions of the authors. Currently,
these pathways are constructed by hand as graphic images
and updated by the scientiﬁc community every 2 years.
Dates of pathway release and updates are posted on the
pathway pages.
LITERATURE ANNOTATIONS
PharmGKB has a collection of pharmaco-related litera-
ture annotations that are generated and enhanced
through hand-curation. We allow reference addition to
PharmGKB either as a Publication entry or as a
Literature Annotation, which includes additional hand-
curated details about the reference and the pharmaco-
genomic relationships described in the article. To aid
users, PharmGKB knowledge generation is achieved by
combining highly searchable controlled vocabulary classi-
ﬁcations of references with brief, detailed free-text
descriptions of the primary research ﬁndings. This
provides users with the most ﬂexible access to the
knowledge we generate about the references, depending
on their diﬀerent needs and preferences.
PHENOTYPE DATA SETS
PharmGKB houses a variety of phenotype data sets. All
phenotype submissions are accepted and PharmGKB has
expanded submission methods to include Microsoft Oﬃce
documents, or alternatively, a URL to another established
archival public database (e.g. GEO). High-impact pheno-
type data sets are curated by hand, while others receive
minimal oversight at PharmGKB. High-impact phenotype
data sets correspond to genotype data submitted to
PharmGKB and are typically published in peer-review
journals. These data are featured on the PharmGKB
website with an interactive display, curated annotations
and downloadable Excel ﬁles. All phenotype ﬁles on
PharmGKB are fully text-searchable. PharmGKB also
oﬀers links to web sites with controlled vocabularies in
Figure 5. PharmGKB phenotype data set. PharmGKB displays phenotype data. In the ﬁgure, there are ﬁve tabs: (i) Overview presents key indexing
terms and a summary of the ﬁle, (ii) Publications points to key publication summaries, (iii) Column Headers deﬁnes the data present in the ﬁle and
(iv) Individualized Data provides a data browser to look at the primary data. (v) External Data Links point to external data sources relevant to the
data set, such as exon arrays stored in other databases.
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tion of their deposits.
The phenotype data set knowledge is available to the
general public via an integrated tab-display (Figure 5).
For all data sets in PharmGKB, genes, drugs, diseases and
categories of pharmacogenetic evidence are tagged and
indexed for querying. Curated phenotype data sets are
reviewed and include meaningful phenotypic annotations
related to pharmacogenomic research, from clinical-
metabolite data to protein constructs. Genotype and/or
phenotype data can be downloaded by clicking on arrows
in the upper right corner of the webpage.
FUTURE DIRECTIONS
PharmGKB catalyzes the generation of new knowledge in
pharmacogenomics through the development, implemen-
tation and dissemination of a public resource focused on
both data and knowledge. In the short-term, this resource
will facilitate basic research. In the long-term, it will
impact how medicine is delivered. Our future work focuses
on detailed annotation of individual human polymorph-
isms (or haplotypes) that are important for drug response
phenotypes. We also are active in creating consortia of
investigators interested in pooling pharmacogenomic data
sets in order to improve population coverage and
statistical power.
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